LRRK2 and Parkinson's disease: from genetics to targeted therapy
Yuri L Sosero1,2, Ziv Gan-Or1,2,3
1Montreal Neurological Institute, McGill University, Montréal, Québec, H3A 1A1, Canada.
Abstract:
LRRK2 variants are implicated in both familial and sporadic PD. LRRK2-PD has a generally benign clinical presentation and variable pathology, with inconsistent presence of Lewy bodies and marked Alzheimer's disease pathology. The mechanisms underlying LRRK2-PD are still unclear, but inflammation, vesicle trafficking, lysosomal homeostasis, and ciliogenesis have been suggested, among others. As novel therapies targeting LRRK2 are under development, understanding the role and function of LRRK2 in PD is becoming increasingly important. Here, we outline the epidemiological, pathophysiological, and clinical features of LRRK2-PD, and discuss the arising therapeutic approaches targeting LRRK2 and possible future directions for research.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Lysosomal Hydrolases
Targeted Cancer Therapies
There are several types of targeted therapies against...
Neural Regulation
EPS and iPS Cells in Disease Research


